MedPath

Tenapanor Hydrochloride

Generic Name
Tenapanor Hydrochloride
Clinical Trials
Related News

Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis

Phase 3
Completed
Conditions
Hyperphosphatemia
Interventions
First Posted Date
2021-02-25
Last Posted Date
2023-08-02
Lead Sponsor
Kyowa Kirin Co., Ltd.
Target Recruit Count
213
Registration Number
NCT04771780
Locations
🇯🇵

Medical Corporation Seijinkai Ikeda Hospital, Kanoya, Kagoshima, Japan

Clinical Study of KHK7791 in Hyperphosphatemia Patients on Peritoneal Dialysis

Phase 3
Completed
Conditions
Hyperphosphatemia
Interventions
First Posted Date
2021-02-23
Last Posted Date
2022-01-11
Lead Sponsor
Kyowa Kirin Co., Ltd.
Target Recruit Count
54
Registration Number
NCT04766385
Locations
🇯🇵

Inoue Hospital, Suita, Osaka, Japan

Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis

Phase 3
Completed
Conditions
Hyperphosphatemia
Interventions
Drug: Placebo
First Posted Date
2021-02-23
Last Posted Date
2021-10-28
Lead Sponsor
Kyowa Kirin Co., Ltd.
Target Recruit Count
169
Registration Number
NCT04766398
Locations
🇯🇵

Inoue Hospital, Suita, Osaka, Japan

Clinical Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis

Phase 3
Completed
Conditions
Hyperphosphatemia
Interventions
Drug: Placebo
First Posted Date
2021-02-23
Last Posted Date
2021-09-08
Lead Sponsor
Kyowa Kirin Co., Ltd.
Target Recruit Count
165
Registration Number
NCT04767581
Locations
🇯🇵

Kikuchi medical clinic, Tsukuba, Ibaraki, Japan

Dose-finding Study of KHK7791 in Hyperphosphatemia Patients

Phase 2
Completed
Conditions
Hyperphosphatemia
Interventions
Drug: Placebo
First Posted Date
2019-03-06
Last Posted Date
2024-03-07
Lead Sponsor
Kyowa Kirin Co., Ltd.
Target Recruit Count
207
Registration Number
NCT03864458
Locations
🇯🇵

Study Site 1, Nagoya, Japan

Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients

Phase 2
Completed
Conditions
Hyperphosphatemia
Interventions
Drug: Placebp
First Posted Date
2019-03-06
Last Posted Date
2024-03-07
Lead Sponsor
Kyowa Kirin Co., Ltd.
Target Recruit Count
47
Registration Number
NCT03864445
Locations
🇯🇵

Study Site 1, Chiba, Japan

A Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on HD

Phase 2
Completed
Conditions
Hyperphosphatemia
Interventions
First Posted Date
2019-02-06
Last Posted Date
2024-03-07
Lead Sponsor
Kyowa Kirin Co., Ltd.
Target Recruit Count
67
Registration Number
NCT03831607
Locations
🇯🇵

Study Site 1, Niigata, Japan

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RDX5791 in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2016-06-30
Last Posted Date
2016-06-30
Lead Sponsor
Ardelyx
Target Recruit Count
80
Registration Number
NCT02819687

Safety, Tolerability, and Pharmacodynamics of RDX5791 in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2016-06-10
Last Posted Date
2016-06-10
Lead Sponsor
Ardelyx
Target Recruit Count
105
Registration Number
NCT02796131

A Phase 1 Study to Examine the Effect of Renvela on the Pharmacodynamics of AZD1722

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2015-01-27
Last Posted Date
2015-01-27
Lead Sponsor
Ardelyx
Target Recruit Count
16
Registration Number
NCT02346890
Locations
🇺🇸

Healthcare Discoveries, LLC, San Antonio, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy